Literature DB >> 29417214

Trends in treatment strategies for suspected bacterial endophthalmitis.

Greg D Fliney1, Paula E Pecen2, Jennifer N Cathcart3, Alan G Palestine3.   

Abstract

PURPOSE: To describe how vitreoretinal specialists have incorporated the Endophthalmitis Vitrectomy Study (EVS) findings into current practice, to highlight divergences from the EVS recommendations, and address the role of microbial culture in guiding additional treatments.
METHODS: This is a cross-sectional survey of vitreoretinal specialists regarding indications used for performing a pars plana vitrectomy (PPV), selection of antibiotics for treatment, utilization of cultures, and treatment strategies for treatment-refractory patients with bacterial endophthalmitis.
RESULTS: Of 681 physicians contacted, 149 (21.9%) responded. For patients with visual acuity of light perception or less, 75% of respondents utilized PPV. Intravitreal vancomycin and ceftazidime were used by 100% and 96% of participants respectively. Vitreal cultures were obtained more than 50% of the time by 86.5% of participants, and were used to influence retreatment less than 50% of the time by 77.8% of respondents. For patients with worsening clinical signs 48 hours after initial treatment, 69.8% of participants performed PPV with intravitreal antibiotics.
CONCLUSIONS: Although most respondents followed the EVS guidelines, a minority deviated, and the majority generalized their strategy to other forms of endophthalmitis. There is significant variation in retreatment strategies, and while cultures are frequently obtained to help guide these treatments, they are utilized infrequently.

Entities:  

Keywords:  Cataract surgery; Endophthalmitis; Endophthalmitis Vitrectomy Study (EVS); Intravitreal antibiotic; Vitrectomy

Mesh:

Substances:

Year:  2018        PMID: 29417214     DOI: 10.1007/s00417-018-3910-3

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  31 in total

1.  Causes of cataract surgery malpractice claims in England 1995-2008.

Authors:  Nadeem Ali; Brian C Little
Journal:  Br J Ophthalmol       Date:  2010-08-30       Impact factor: 4.638

2.  Persistently Vitreous Culture-Positive Exogenous Bacterial Endophthalmitis.

Authors:  Ella H Leung; Ajay E Kuriyan; Harry W Flynn; Darlene Miller; Laura C Huang
Journal:  Am J Ophthalmol       Date:  2016-02-26       Impact factor: 5.258

3.  Intracameral Antibiotics and Cataract Surgery: Endophthalmitis Rates, Costs, and Stewardship.

Authors:  Stephen G Schwartz; Harry W Flynn; Andrzej Grzybowski; Nidhi Relhan; Frederick L Ferris
Journal:  Ophthalmology       Date:  2016-07       Impact factor: 12.079

4.  Evaluation of microbiological diagnostic techniques in postoperative endophthalmitis in the Endophthalmitis Vitrectomy Study.

Authors:  M Barza; P R Pavan; B H Doft; S R Wisniewski; L A Wilson; D P Han; S F Kelsey
Journal:  Arch Ophthalmol       Date:  1997-09

Review 5.  Endophthalmitis following open-globe injuries.

Authors:  Y Ahmed; A M Schimel; A Pathengay; M H Colyer; H W Flynn
Journal:  Eye (Lond)       Date:  2011-12-02       Impact factor: 3.775

6.  Endogenous bacterial endophthalmitis. Report of a ten-year retrospective study.

Authors:  A A Okada; R P Johnson; W C Liles; D J D'Amico; A S Baker
Journal:  Ophthalmology       Date:  1994-05       Impact factor: 12.079

Review 7.  Endogenous bacterial endophthalmitis: a 17-year prospective series and review of 267 reported cases.

Authors:  Timothy L Jackson; Susannah J Eykyn; Elizabeth M Graham; Miles R Stanford
Journal:  Surv Ophthalmol       Date:  2003 Jul-Aug       Impact factor: 6.048

Review 8.  Endophthalmitis: a review of current evaluation and management.

Authors:  Craig A Lemley; Dennis P Han
Journal:  Retina       Date:  2007 Jul-Aug       Impact factor: 4.256

9.  Comparison of methods for identifying causative bacterial microorganisms in presumed acute endophthalmitis: conventional culture, blood culture, and PCR.

Authors:  Pear Pongsachareonnont; Worawalun Honglertnapakul; Tanittha Chatsuwan
Journal:  BMC Infect Dis       Date:  2017-02-21       Impact factor: 3.090

10.  Five-Port Combined Limbal and Pars Plana Vitrectomy for Infectious Endophthalmitis.

Authors:  Kunyong Xu; Eric K Chin; David R P Almeida
Journal:  Case Rep Ophthalmol       Date:  2016-12-13
View more
  6 in total

1.  Therapeutic Effects of Intravitreously Administered Bacteriophage in a Mouse Model of Endophthalmitis Caused by Vancomycin-Sensitive or -Resistant Enterococcus faecalis.

Authors:  Tatsuma Kishimoto; Waka Ishida; Ken Fukuda; Isana Nakajima; Takashi Suzuki; Jumpei Uchiyama; Shigenobu Matsuzaki; Daisuke Todokoro; Masanori Daibata; Atsuki Fukushima
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

2.  Dual Drug Loaded Lipid Nanocarrier Formulations for Topical Ocular Applications.

Authors:  Ahmed Adel Ali Youssef; Narendar Dudhipala; Soumyajit Majumdar
Journal:  Int J Nanomedicine       Date:  2022-05-18

3.  Complete and Early Vitrectomy for Endophthalmitis After Cataract Surgery: An Alternative Treatment Paradigm.

Authors:  Bernard Dib; Robert E Morris; Matthew H Oltmanns; Mathew R Sapp; Jay P Glover; Ferenc Kuhn
Journal:  Clin Ophthalmol       Date:  2020-07-08

4.  Clinical analysis and predictive factors associated with improved visual acuity of infectious endophthalmitis.

Authors:  Zhao Gao; Yunda Zhang; Xiaohong Gao; Ximei Zhang; Tao Ma; Gaiyun Li; Jingjing Wang; Hua Yan
Journal:  BMC Ophthalmol       Date:  2020-06-29       Impact factor: 2.209

Review 5.  Endophthalmitis: Changes in Presentation, Management and the Role of Early Vitrectomy.

Authors:  Emily H Shao; William B Yates; I-Van Ho; Andrew A Chang; Matthew P Simunovic
Journal:  Ophthalmol Ther       Date:  2021-10-25

6.  Study of the Correlation Between Severity of Endophthalmitis and Posterior Vitreous Detachment Using a Rabbit Endophthalmitis Model.

Authors:  Ryo Baba; Kazuhiko Umazume; Naohito Koike; Hiroshi Goto
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-02-01       Impact factor: 4.799

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.